Navigation Links
Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto l'endpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
Date:9/17/2013

uppo trattato con alogliptin e in quello trattato con placebo, e la differenza delle medie least square di HbA1c tra alogliptin e placebo è stata di -0,36% (95% CI, -0,43, -0,28, p<0.001). Nell'analisi dei componenti dell'endpoint primario le hazard ratio erano coerenti con i risultati globali. Le hazard ratio per morte per tutte le cause e per morte per cause cardiovascolari erano coerenti con l'endpoint primario composito.

Takeda ha condotto lo studio globale EXAMINE in conformità con quanto previsto dalla Guida 2008 della Food and Drug Administration (FDA) degli Stati Uniti (US), dal titolo "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes", per tutti i nuovi trattamenti per il diabete di tipo 2. Trattandosi di uno studio globale, i risultati di EXAMINE saranno condivisi con le agenzie regolatorie una volta completate tutte le analisi, come appropriato.

Informazioni sul diabete di tipo 2
Il diabete di tipo 2 è la forma più comune di diabete che interessa milioni di persone in tutto il mondo. Il diabete di tipo 2 è una condizione cronica e progressiva e i pazienti devono lavorare insieme a professionisti della sanità per gestire e monitorare la loro patologia. In aggiunta alla dieta e all'esercizio fisico, i pazienti devono spesso assumere uno o più medicinali che li aiutino a controllare i livelli di glucosio nel sangue. Secondo la International Diabetes Federation, la spesa sanitaria mondiale per il diabete (sia di tipo 1 che di tipo 2) è stata stimata maggiore di 471 miliardi di dollari USA nel 2012. Entro il 2030, si prevede che questa cifra supererà i 595 miliardi di dollari US.

Informazioni su Alogliptin
Alogliptin è un inibitore del dipeptidil peptidasi-4 (DPP-4i) per il trattamento del diabete di tipo 2 negli adulti, in aggiunta alla dieta e all'esercizio fisico. I DPP-
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anthony Creed Joins DDSTUDIO As GM, Experience Design
2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
4. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
5. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
6. River City Laser Tattoo Removal Studio Offers Grand Opening Discounts on Treatments Using the Astanza Revolution Laser
7. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
8. New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments
9. Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
10. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
11. The Food Journal Examines Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
(Date:7/31/2014)... Calif., July 31, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... ended July 4, 2014 of $20.0 million, a 10% ... of 2013. On a constant currency basis, revenues grew ... the second quarter of 2013.  The effect of foreign ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 9th, the Hooters of Orange Park is hosting a car wash ... begins at 10 AM at the Hooters of Orange Park located ... 215-5858. All donations from the car wash will go toward the ... Hooters restaurant in the country is raising money through various charitable ...
... Taking a Vitamin with Folic Acid Before PregnancyWHITE PLAINS, ... supplements for at least one year before they become ... baby by half, according to research published this week ... folate supplementation of at least one year to reduced ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2
(Date:7/31/2014)... July 31, 2014 Etymotic Research, ... a new sponsorship of the DrumLine Battle® series ... Etymotic’s hearing protection products ETY•Plugs® and Music•PRO® electronic ... the harmful effects of high-level sound. Etymotic will ... at the Drum Corps International Championships on August ...
(Date:7/31/2014)... Most mommy blogs are simple family journals, ... to attract all mothers from all walks of life. ... whether its high fashion or child rearing. When Felicia ... the Internet was so segmented. “I found myself visiting ... and then search Google to get information on another. ...
(Date:7/31/2014)... and saliva tests that help accurately predict recurrences of ... The tests screen for DNA fragments of the human ... mouth or other parts of the body. A description ... issue of JAMA Otolaryngology Head & Neck ... in the year after initial therapy to take an ...
(Date:7/31/2014)... LDM Global ( http://www.ldmglobal.com ) announces the ... simplified and predictable with fixed fees across the board, ... international provider of legal discovery management services for law ... apparent that both the courts and legal counsel alike ... complex pricing structure that plagues the litigation support industry. ...
(Date:7/31/2014)... By Steven Reinberg ... (HealthDay News) -- Many obese and overweight kids don,t ... weight almost impossible, researchers report. In a new ... weight. Fewer than 3 percent overestimated it. About 25 ... 1 percent overestimated it, according to the study. ...
Breaking Medicine News(10 mins):Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Mommylish Launches Its Website 2Health News:Blood and saliva tests help predict return of HPV-linked oral cancers 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 3
... Mann HealthDay Reporter , TUESDAY, Feb. 21 (HealthDay ... take a second look at the weight loss pill Qnexa ... heart problems and possible birth defects. While effective at ... approval in 2010 because of its potential side effects. An ...
... HOUSTON By reformulating the common cancer drug imatinib ... an important step toward improving the effectiveness of chronic ... University of Texas MD Anderson Cancer Center. Narcotics ... treatment. Over time, tolerance to the pain-relieving effects of ...
... 2012 A simple blood test is being developed by ... University Medical Center in Beer-Sheva, Israel that may provide early ... BGU,s Faculty of Health Sciences and his team developed a ... of blood. The test uses infrared light to detect miniscule ...
... telomerase, an enzyme that rescues malignant cells from destruction by ... tumor cells but also triggers resistance pathways that allow cancer ... issue of Cell . "Telomerase is overexpressed in ... target requires us to understand what it does and how ...
... Cedars-Sinai research scientist has been awarded two national grants ... Project Grant from the National Institutes of Health to ... Terrence Town, PhD, is studying drugs that potentially could ... that build up in the brain and are widely ...
... cell that regulate metabolism and energy use, may be ... a new study. Manipulation of two biochemical signals that ... human lung cancers transplanted into mice, a team of ... Within each cell, mitochondria are constantly splitting in ...
Cached Medicine News:Health News:FDA Weighs Fate of Qnexa for Weight Loss, Again 2Health News:FDA Weighs Fate of Qnexa for Weight Loss, Again 3Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 3Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 4Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:Energy network within cells may be new target for cancer therapy 2Health News:Energy network within cells may be new target for cancer therapy 3
Provides the security of braided polyester suture and ease of an automated knot for vascular closure of 5-8Fr....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: